Physician profile
Ram Reddy
NPI 1912097155
$4,188.15
in general payments reported to CMS, 2019-2025
32 companies · $715 in 2025
The $715 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $384 · 2021: $514 · 2022: $303 · 2023: $1,477 · 2024: $237 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250 · Food and Beverage: $838 · Travel and Lodging: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
| Food and Beverage | $838.08 |
| Travel and Lodging | $340.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,717.41 | 2021-2025 | |
| Medtronic, INC. | $340.09 | 2025 | Octopus |
| Allergan, INC. | $230.09 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $161.53 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $158.46 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $124.47 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $123.65 | 2019-2021 | |
| Amarin Pharma, INC. | $122.18 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $118.07 | 2019-2020 | |
| Amgen INC. | $117.49 | 2019-2024 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $106.07 | 2020-2021 | |
| Lilly USA, LLC | $103.69 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $101.14 | 2019-2022 | |
| Pfizer INC. | $66.71 | 2019-2025 | |
| Abbott Laboratories | $64.33 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $64.32 | 2024-2025 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $60.62 | 2020-2024 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $57.08 | 2019-2021 | |
| Sanofi Pasteur INC. | $41.92 | 2022-2023 | |
| Axsome Therapeutics, INC. | $38.53 | 2025 | Auvelity |
| Astellas Pharma US INC | $36.98 | 2021-2024 | Veozah |
| Revance Therapeutics, INC. | $30.96 | 2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $26.68 | 2025 | Evkeeza |
| Idorsia Pharmaceuticals US INC | $25.96 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $25.36 | 2021-2022 | |
| C2n Diagnostics, LLC | $25.32 | 2025 | Precivityad2 |
| Corcept Therapeutics | $23.79 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.40 | 2019 | |
| Genentech USA, INC. | $16.17 | 2020 | |
| Exact Sciences Corporation | $16.13 | 2024 | Cologuard Collection Kit |
| Linus Health, INC. | $15.04 | 2023 | |
| Melinta Therapeutics, LLC | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.